Y. Kai, S. Chiku
Nov 1, 1994
Citations
0
Influential Citations
2
Citations
Journal
Journal of Labelled Compounds and Radiopharmaceuticals
Abstract
(−)-(RS)-(E)-3-[(6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-fluoromethoxyiminoacetamide]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-3-yl[-2-propenyl](carbamoylmethyl) ethylmethylammonium hydroxide inner salt (E1077), a new parenteral cephalosporin with well-balanced antibacterial spectrum and potent antibacterial activity, was labelled with carbon-14, starting from potassium [14C]thiocyanate which on reaction with (Z)-2-(N-chloroamidino)-2-fluoromethoxyiminoacetic acid (I) gave(Z)-2-(5-amino-1,2,4-[5-14C]thiadiazol-3-yl)-2-fluoromethoxyiminoacetic acid (II). (RS)-[(E)-3-](6R,7R)-7-Amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-3-yl[-2-propenyl](carbamoylmethyl) ethylmethylammonium hydroxide inner salt (III) was acylated with the above acid using the POCl3-DMF method, to afford the title compound (IV); [14C]E1077, having a specific activity of 3.36 MBq/mg, was obtained in 50.3% overall radiochemical yield, with a radiochemical purity of more than 97.1%.